Alembic Pharmaceuticals Limited has informed the Exchange about change in Management
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alembic Pharmaceuticals has informed the stock exchanges that Mr. Nilesh Wadhwa, Head – Formulation Business Development (also referred to as Head – International Business & Strategy), has resigned from his position effective 31st March 2026 (after closure of business hours). He originally submitted his resignation letter on 16th December 2025, requesting a relieving date around June 2026, though the company confirmed his exit at the end of March 2026. No reason for departure has been disclosed beyond the voluntary resignation. The filing was made under Regulation 30 of SEBI LODR read with the latest SEBI master circular on disclosure of such changes.
This is a senior management-level exit, not a CEO or CFO change, so direct stock price impact is likely limited. However, investors should watch for the company's succession plan for the formulation/international business head, as continuity in this revenue-driving function will be important.